Science and Innovations in MedicineScience and Innovations in MedicineНаука и инновации в медицине2500-13882618-754XFSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation70605810.35693/SIM706058Original study articlesОригинальные исследованияThe role of HGF, CEA, IL-8, and prolactin in progression of colorectal cancer, their diagnostic potential, and as therapeutic targetsРоль HGF, CEA, IL-8 и пролактина в прогрессировании колоректального рака, их диагностический потенциал и роль в качестве терапевтических мишенейhttps://orcid.org/0000-0002-1503-3759UchenduIkenna Kingsleyuchenduikenna1@gmail.comhttps://orcid.org/0000-0002-0060-2197ZhilenkovaAngelina Vladimirovna
Russian Federation

младший научный сотрудник Института персонализированной онкологии Научно-технологического парка биомедицины

av.zhilenkova@gmail.comOrlovaEkaterina Vadimovnaorlovaderm@yandex.ruhttps://orcid.org/0000-0003-3311-3290NikitinaNatalia Mihailovna
Russian Federation
nikitina_n_m@staff.sechenov.ruRozhkovAlexandervisperianlol@gmail.comhttps://orcid.org/0000-0001-6990-0291BagmetLeonid NikolaevichBagmetln@mail.ruhttps://orcid.org/0000-0003-0015-7094SekachevaMarina Igorevnasekach_rab@mail.ru1. Кафедра медицинской лабораторной диагностики, факультет здравоохранения и технологий, медицинский колледж, Университет Нигерии, кампус в Энугу 2. ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет), Москва, РоссияSechenov First Moscow State Medical UniversityФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет), Москва, Россия300620261304202612052026Copyright ©; , Uchendu I., Zhilenkova A.V., Orlova E.V., Nikitina N.M., Rozhkov A., Bagmet L.N., Sekacheva M.I.Copyright ©; , Uchendu I., Zhilenkova A., Orlova E., Nikitina N., Rozhkov A., Bagmet L., Sekacheva M.Uchendu I., Zhilenkova A.V., Orlova E.V., Nikitina N.M., Rozhkov A., Bagmet L.N., Sekacheva M.I.Uchendu I., Zhilenkova A., Orlova E., Nikitina N., Rozhkov A., Bagmet L., Sekacheva M.https://creativecommons.org/licenses/by/4.0https://innoscience.ru/2500-1388/article/view/706058

Aim. To evaluate the role of HGF, CEA, IL-8, and prolactin in progression of colorectal cancer, their diagnostic potential, and as therapeutic targets.

Materials and Methods. In this cross-sectional study, Luminex xMAP 200 was used to determine serum cytokine profiles in 91 CRC stages I–IV patients and 100 healthy controls, identifying diagnostic indicators. Mann-Whitney U and Kruskal-Wallis H tests were used to compare groups; heatmap and receiver operating characteristic (ROC) were used to analyze cytokine-CRC relationships.

Results. Significant variations in prolactin (p=0.004), hepatocyte growth factor (HGF) (p=0.01), interleukin-8 (IL-8) (p=0.01), and carcinoembryonic antigen (CEA) (p=0.01) indicated that the inflammatory milieu was favorable for malignancies. There was a substantial correlation between CEA and CRC staging. For HGF (AUC =0.780), CEA (AUC=0.733), IL-8 (AUC=0.729), and prolactin (AUC=0.708), ROC analysis demonstrated good diagnostic performance. The findings suggest that a systemic inflammatory environment is encouraging angiogenesis and tumor formation. The study has highlighted potential diagnostic indicators for CRC.

Conclusion. HGF, IL-8, CEA, and prolactin are potential diagnostic markers linked to colorectal cancer progression and staging in patients who may benefit from serum HGF, IL-8, CEA, and prolactin monitoring and the therapeutic target of their genes.

colorectal cancer, HGF, IL-8, CEA, prolactin, cancer stagingNone.1. Kaur R., Bhardwaj A, Gupta S. Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep 2023; 50(11):9663-9676. https://doi.org/10.1007/s11033-023-08809-32. Hojman P. Exercise protects from cancer through regulation of immune function and inflammation. Biochem Soc Trans. 2017;45(4):905-911. https://doi.org/10.1042/BST201604663. Bower JE, Greendale G, Crosswell AD, et al. Yoga Psychoneuroendocrinol. 2014;43:20-29. https://doi.org/10.1016/j.psyneuen.2014.01.0194. Marelli G, Sica A, Vannucci L, et al. Inflammation as target in cancer therapy. Curr Opin Pharmacol 2017;35:57-65. https://doi.org/10.1016/j.coph.2017.05.0075. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: Cancer J Clin. 2024;74(1):12-49. https://doi.org/10.3322/caac.218206. Khosravi N, Stoner L, Farajivafa V, et al. Exercise training, circulating cytokine levels and immune function in cancer survivors: a meta-analysis. Brain, Behav, Immun. 2019;81:92-104. https://doi.org/10.1016/j.bbi.2019.08.1877. Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nature Rev Cancer. 2021;21(6):345-59. https://doi.org/10.1038/s41568-021-00347-z8. Kruijsen-Jaarsma M, Révész D, Bierings MB, et al., Effects of exercise on immune function in patients with cancer: a systematic review. Exerc Immunol Rev. 2013;19: 120-143.9. Stoner L, Lucero AA, Palmer BR, et al. Inflammatory biomarkers for predicting cardiovascular disease. Clin Biochem. 2013;46(15):1353-1371. https://doi.org/10.1016/j.clinbiochem.2013.05.07010. Singh N, Baby D, Rajguru JP, et al. Inflammation and cancer. Ann Afr Med 2019;18(3):121-126. https://doi.org/10.4103/aam.aam_56_1811. Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27-41. https://doi.org/10.1016/j.immuni.2019.06.02512. Yao J, Caballero OL, Yung WA, et al. Tumor subtype-specific cancer–testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res 2014;2(4):371-9. https://doi.org/10.1158/2326-6066.CIR-13-008813. Kartikasari AE, Huertas CS, Mitchell A, et al. Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis. Front Oncol. 2021;11:692142. https://doi.org/10.3389/fonc.2021.69214214. Essogmo FE, Zhilenkova AV, Tchawe YSN., et al. Cytokine profile in lung cancer patients: anti-tumor and oncogenic cytokines. Cancers, 2023;15(22), 5383. https://doi.org/10.3390/cancers1522538315. Uchendu I, Zhilenkova A, Pirogova Y, et al. Cytokines as potential therapeutic targets and their role in the diagnosis and prediction of cancers. Curr Pharm Des 2023; 29(32), 2552-2567. https://doi.org/10.2174/011381612826811123102405424016. Naing L, Winn T, Rusli BN. Sample size calculation for prevalence studies. Arch. Orofac. Sci., 2006, 1, 9-149.17. WHO Fact Sheet. Colorectal cancer 2023[Available at] https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer. Accessed on: [November 17, 2025],18. Sobin LH, Compton CC. TNM seventh edition: What's new, what's changed. Cancer. 2010;116(22):5336-5339. https://doi.org/10.1002/cncr.2553719. Ngaha TY, Zhilenkova AV, Essogmo FE, et al. Angiogenesis in lung cancer: understanding the roles of growth factors. Cancers. 2023;15(18):4648. https://doi.org/10.3390/cancers1518464820. Burgos-Molina AM, Téllez Santana T, Redondo M, et al. The crucial role of inflammation and the immune system in colorectal cancer carcinogenesis: a comprehensive perspective. Int J Mol Sci. 2024;25(11):6188.https://doi.org/10.3390/ijms2511618821. Bhat AA, Nisar S, Singh M, et al. Cytokine‐and chemokine‐induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy. Cancer Commun. 2022;42(8):689-715. https://doi.org/10.1002/cac2.1229522. Gulhati P, Yin J, Pederson L, et al. Threshold change in CEA as a predictor of non-progression to first-line systemic therapy in metastatic colorectal cancer patients with elevated CEA. JNCI: J Natl Cancer Inst 2020;112(11):1127-1136. https://doi.org/10.1093/jnci/djaa02023. Jabbarzadeh Kaboli P, Roozitalab G, Farghadani, R, et al. c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity. Front Immunol 2024;15:1498391. https://doi.org/10.3389/fimmu.2024.149839124. Bou Antoun N, Chioni, AM. Dysregulated signalling pathways driving anticancer drug resistance. Int J Mol Sci. 2023;24(15):12222. https://doi.org/10.3390/ijms24151222225. Lin S, Zhou C, Chen H, et al. Advances in hereditary colorectal cancer: how precision medicine is changing the game. Cancers. 2025;17(21):3461. https://doi.org/10.3390/cancers1721346126. David JM, Dominguez C, Hamilton DH, et al. The IL-8/IL-8R axis: a double agent in tumor immune resistance. Vaccines. 2016;4(3):22. https://doi.org/10.3390/vaccines403002227. Gales D, Clark C, Manne U, et al. The chemokine CXCL8 in carcinogenesis and drug response. Int Sch Res Notices 2013;2013(1):859154.https://doi.org/10.1155/2013/85915428. Tsai CW, Chang WS, Yueh TC. et al. The significant impacts of interleukin-8 genotypes on the risk of colorectal cancer in Taiwan. Cancers. 2023;15(20):4921. https://doi.org/10.3390/cancers1520492129. Sobah M.L, Liongue C, Ward AC. SOCS proteins in immunity, inflammatory diseases, and immune-related cancer. Front Med. 2021;8:727987. https://doi.org/10.3389/fmed.2021.727987